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Abstract: Brains from 41 aged canines (≥10 years of age) were examined 
immunohistochemically to characterize the laminar distribution and age-
related progression of β-amyloid (Aβ) in frontal cortex. We classified the Aβ 
patterns into four distinct types. Type I was characterized by small, faint 
deposits of Aβ in deep cortical layers. Type II consisted of diffuse deposits of 
Aβ mainly in layers V and VI. Type III had both dense plaques in superficial 
layers, and diffuse deposits in deep layers. Finally, Type IV had solely dense 
plaques throughout all layers of cortex. We compared the Aβ distribution 
pattern between the Old canines (10–15 years, n=22) and the Very Old 
canines (>15 years, n=19). The Old group primarily had negative staining, or 
Type I and Type II patterns of amyloid deposition (73%). Conversely, the 
Very Old group had predominantly Types II, III and IV deposits (89.5%), a 
difference that was significant (P<0.05). We suggest that Aβ deposition in 
canine frontal cortex is a progressive age-related process beginning with 
diffuse deposits in the deep cortical layers followed by the development of 
deposits in outer layers. In support of this hypothesis, the deeper layer 
diffuse plaques in the Very Old group of dogs also contain the largest 
proportion of β-amyloid with an isomerized aspartic acid residue at position 7, 
indicating that these deposits had been present for some time. We also 
observed fiber-like Aβ immunoreactivity within regions of diffuse Aβ deposits. 
These fibers appeared to be degenerating neurites, which were negative for 
hyperphosphorylated tau. Therefore, these fibers may represent a very early 
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form of neuritic change that precede tau hyperphosphorylation or develop by 
an alternative pathway. 
Keywords : Diffuse plaque, Plaque type, Isoaspartate β-amyloid, Aging, 
Alzheimer's, Animal model, Beagle dog lifespan 
1. Introduction 
The classical neuropathological hallmarks of Alzheimer's disease 
(AD) are the progressive accumulation of extracellular β-amyloid (Aβ) 
within the parenchyma that form senile plaques, and intraneuronal 
cytoskeletal changes, which result in neurofibrillary tangles (NFTs).3 It 
has become clear that different plaque subtypes are present within the 
brains of aged non-demented individuals and AD patients. These 
plaque subtypes appear to progress through specific, identifiable 
stages beginning with diffuse, non-β-pleated structures followed by 
primitive plaques and then neuritic plaques, which are thioflavine- and 
Congo-red-positive.7 Characterizing the development of these lesions 
and their relation to NFTs is critical to understanding the pathogenesis 
of AD. However, the study of these processes is exceptionally difficult 
using human tissue because they occur over the course of years. 
Previously, we suggested that the aged canine is a model 
system particularly well-suited to the investigation of the initial stages 
of plaque formation.6,8 The aged canine brain contains predominantly 
diffuse plaques. Furthermore, the incidence of plaque formation in the 
aged canine population is relatively high, without showing the classical 
feature of neurofibrillary tangle formation. Thus, this model may be 
useful for delineating the mechanisms involved in the initial stages of 
Aβ deposition and for studying the processes that promote plaque 
development into degenerative loci in the absence of tangles.8 Such an 
animal model is necessary, since it is difficult to study early AD 
pathology in the human brain due to the reserve capacity of the brain 
to absorb damage,25 and the rarity of early-stage autopsy tissue. 
In addition to early neuropathological changes being present in 
many aged canine brains, it has been reported that canines experience 
age-related cognitive dysfunction. Aged canines are impaired on a 
variety of tasks, including delayed non-matching-to-sample recognition 
learning and spatial learning.15,22 Further, it has been reported that 
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various kinds of cognitive dysfunction in the aged canine correlate with 
the extent of Aβ deposition in hippocampus and frontal cortex.6 
Accordingly, study of the aged canine brain may also aid in our 
understanding of the morphological and cognitive changes that occur 
in aging. 
It is generally assumed that NFTs and Aβ deposits in the human 
brain are not distributed randomly, but rather they have a 
characteristic regional and laminar pattern.3 The research literature 
regarding the laminar distribution of senile plaques in AD brain, 
however, is less than definitive.20,24,27 For example, Braak et al. 
reported that neuritic plaques are predominantly found in layers II and 
III of occipital isocortex,4 while Lewis and co-workers reported that 
neuritic plaques are most numerous in layers III and IV of the visual 
and auditory cortices.20 In fact, several investigators suggest that 
plaques are more common in the superficial cortical layers compared 
with deeper layers,10,11,26 while others suggest just the opposite.30,31 
The apparent variability in the laminar specificity of plaque distribution 
in AD may be due in part to the variability in the disease stage of the 
cases examined in each study. As a result, characterizing the laminar 
distribution of Aβ deposits with advancing age in the canine cortex 
could help to clarify the distribution and progression of Aβ in AD brain. 
Therefore, in the present study we sought to characterize the 
distribution and progression of pathological changes in AD by use of an 
animal model of senile plaque formation. Specifically, we sought to 
clarify the laminar distribution of Aβ within the frontal cortex of aged 
canines and to delineate the progression of Aβ deposition over time 
using Aβ immunocytochemistry and a large sample of aged canines. 
Because one consequence of amyloid deposition over a long period of 
time is the spontaneous isomerization of aspartic acid residues present 
at positions 1 and 7 of the β-amyloid peptide,28 we also used an 
affinity purified antibody specific for the isomerized form of β-amyloid 
to further investigate a progression hypothesis. We chose frontal 
cortex because it has been suggested that the distribution of Aβ is 
more consistent in frontal cortex than in the hippocampus, based on 
analyses of human brain.25 
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2. Materials and methods 
Thirty-two of the 41 animals in the study were beagles from the 
Inhalation Toxicology Research Institute's (ITRI) animal colony in 
Albuquerque, New Mexico. There were 27 females and 5 males. The 
age of these dogs ranged from 10.4 to 17.7 years at death (see Table 
1). These dogs were part of a study designed to evaluate the health 
effects of the monoamine oxidase inhibitor l-deprenyl on young adult 
and aged beagles. Thus, they were treated with l-deprenyl (1 
mg/kg/day) or placebo once a day for approximately 2 years 10 
months. The time between cessation of treatment varied from 0 days 
to 101 days, depending on the cause of death (i.e. unplanned death, 
euthanasia due to disease, or planned sacrifice). The dogs were 
housed in kennel buildings with indoor and outdoor runs. They were 
fed a dry kibble (Wayne Mini Lab Dog Diet 8759, Teklad Laboratory 
Diets, Madison, WI) once a day over their life span. 
Table 1. Descriptive data (mean±S.E.M., frequencies) on the groups of 
canines 
Group Sex Age (years) Breedb Treatmenta 
Total (41) 6 M, 35 F 14.2±0.4 32 B1, 5 B2, 4 P 19 yes, 22 no 
Old: 10–15 years (22) 2 M, 20 F 12.5±0.4 13 B1, 5 B2, 4 P 7 yes, 15 no 
Very Old: >15 years (19) 4 M, 15 F 16.2±0.2 19 B1, 0 B2, 0 P 12 yes, 7 no 
aTreated with a monoamine oxidase inhibitor (l-deprenyl, 1 mg/kg/day; B1 only), 
others given placebo (B1) or not included in study (B2, P). 
bB1, ITRI beagle; B2, Marshall Farms beagle; P, pound dog (mongrel). 
There were also five beagles born and raised at Marshall Farms 
in NY and four pound mongrels included in the study (Table 1). Two 
were male and seven (including all five beagles) were female, with 
ages ranging from 10.0 to 12.3 years. The age of the four pound dogs 
was based on available records and dentition. 
The ITRI beagles were born and raised in the ITRI dog colony. 
The breeding program was a random, generation type system 
designed to maintain a gene pool as broad as possible. The members 
of each breeding generation were selected randomly from the available 
population, with restrictions placed only on sibling and half-sibling 
matings, and exclusion of dogs with EEG tracings suggestive of 
epilepsy.2 
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The dogs were observed daily by the animal technicians and 
were treated for all detected injuries and illnesses by the veterinary 
staff using standard accepted treatments.18 Dogs that showed signs of 
pain or anxiety that could not be controlled with medication were 
euthanized. Some of the dogs were euthanized as a planned schedule. 
All dogs that died or were euthanized were necropsied as soon as 
possible and all major organs were examined. Major organs and all 
lesions found were sampled for histopathology. A cause of death and 
other significant diseases for each dog were determined from the 
clinical records and pathology information. 
In addition to the dogs included in this study, there were 398 
control dogs that have been cared for in the colony for their entire life 
span. These dogs were used to estimate the life span of the laboratory 
beagle. The survival of this population was determined using a life-
table method of analysis. The BMDP1 L Life Tables and Survival 
Functions statistical software package was used for this analysis. The 
cumulative survival is shown in Fig. 1. The median survival time was 
13.7 years for the males and 13.6 years for the females. The survival 
times were not significantly different as demonstrated by the log-rank 
test. 
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Fig. 1. The cumulative survival curves for male and female control dogs (n=398) at 
the Inhalation Toxicology Research Institute. The median survival times of 13.7 years 
for males and 13.6 years for females were not significantly different (log-rank test). 
Coronal brain sections (1 cm thick) were fixed in 4% 
paraformaldehyde for 2 days and held in 10% neutral buffered 
formalin at post-mortem. Dorsolateral frontal cortex was sectioned 
free-floating (50 μm) using a Vibratome. The sections were pretreated 
with 70% formic acid for 5 min and incubated with an affinity purified 
β-amyloid antibody (Aβ42, 1:1000) or an affinity purified antibody 
directed against isomerized β-amyloid (isoAsp7, 1:1050) using 
standard immune-histochemical procedures.9 Aβ42 is a rabbit 
polyclonal antibody against synthetic Aβ1–42 amyloid peptide. It 
preferentially recognizes full-length Aβ on Western blots and does not 
cross-react with native amyloid precursor protein (APP) in tissue or on 
Western blots.34 IsoAsp is a rabbit polyclonal antibody raised against 
synthetic Aβ1–15 with isoaspartic acid substituted for the aspartic acid 
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at position 7.14 A 16-amino-acid peptide of Aβ1–15 was synthesized (C. 
Glabe, UCI) containing isoAsp at residue 7 and a cysteine at residue 16 
(the carboxy terminus). 500 μl at 2 mg/ml (0.976 μl) of this peptide 
was mixed with 200 μl reconstituted Pierce Maleimide Activated 
Keyhole Limpet Hemocyanin (KLH) (product #77106) at 10 mg/ml 
(0.7 μmol maleimide groups) and allowed to react for 2 h at room 
temperature. Aliquots of this immunogen (isoAsp7-KLH) were then 
frozen and stored at −70°C. For immunization, 375 μl isoAsp7-KLH 
was emulsified with 375 μl Freund's complete adjuvant (FCA) and 
injected (s.c.) into a New Zealand white rabbit. The rabbit was boosted 
with 150–200 μl (s.c.) twice at 2-week intervals with equal volumes of 
immunogen emulsified with Freund's incomplete adjuvant (FIA). One 
week after the first boost and 1 and 2 weeks after the second boost 
the rabbit was bled, screened for the presence of isoAsp7-specific 
antibodies, and rabbit IgG from three pooled bleeds was purified from 
serum using the octanoic acid/ammonium sulfate method. Aβ 
antibodies not specific for isoAsp7 were depleted from rabbit IgG using 
non-isomerized Aβ1–40 conjugated to Reacti-Gel Column (Pierce product 
#20259) three times. Antibodies specific for Aβ IsoAsp7 were then 
affinity purified from the rabbit IgG using the antigenic peptide 
containing isoAsp7 conjugated to Sulfolink coupling gel (Pierce product 
#20401). The eluted antibodies were then rerun over non-isomerized 
Aβ1-40 Recti-Gel Column to remove any remaining antibodies not 
specific for Aβ isoAsp7. The absence of Aβ1-40 cross-reactivity in the 
affinity purified anti-isoAsp7 antibodies was verified by an indirect 
detection ELISA. 
After immunostaining, tissue sections were lightly Nissl counter-
stained to identify the cell layers. After dehydration in a graded series 
of alcohols and penetration with Histoclear (National Diagnostics, 
Atlanta, GA), sections were coverslipped with DePex (BDH Laboratory 
Supplies, Poole, UK). All sections were observed by light microscopy. 
In control experiments, we omitted the primary antibody or used 
normal rabbit serum instead of the primary antibody as negative 
controls. These tests resulted in no staining in the tissue sections. 
To confirm degenerative nerve fibers, we double-labeled for 
Aβ42 and abnormally phosphorylated tau via PHF-1 (monoclonal 
antibody raised in mouse and kindly provided by Dr. S. Greenberg; 
1:200)13 or SMI-311 (Sternberg Monoclonals, Baltimore, MD; 1:600). 
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Following Aβ42 staining and reaction with diaminobenzidine (DAB), the 
tissues were incubated in a second primary antibody overnight and 
then rinsed and incubated for 1.5 h in CY3-conjugated anti-mouse 
immunoglobulin G (IgG) (Jackson ImmunoResearch, 1:200). Sections 
were then washed in phosphate-buffered saline and mounted on 
gelatin-subbed slides with Vectashield (Vector Labs, CA). 
3. Results 
We observed Aβ deposition in nearly all of the aged canines 
examined (95%). While examining Aβ deposition in more than 100 
animals over the past few years, we have noted that there appear to 
be several distinct patterns of Aβ deposition with possible intermediate 
stages. In some animals, large Aβ-immunopositive plaques are present 
within the superficial layers of cortex. In other animals, a diffuse cloud 
of Aβ deposition appears to have spread throughout the deep layers of 
cortex. This diffuse zone of Aβ often measures several millimeters. 
Based on these observations, we classified the morphological patterns 
of Aβ deposition observed in the aged canine brains in the present 
study into four subtypes. These subtypes are depicted in diagrammatic 
form in Fig. 2 and shown photographically in Fig. 3. 
 
Fig. 2. Diagrammatic representation of the predominant patterns of Aβ deposition 
found in the frontal cortex of aged canines. The relative regions of each cortical layer 
are indicated in the left margin. 
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Fig. 3. Representative photomicrographs (×10) of each of the four patterns of Aβ 
deposition found in the frontal cortex of aged canines. Type I is shown in A, type II in 
B, type III in C and type IV in D. Two of the 41 canines exhibited no Aβ 
immunoreactivity. The remaining 39 animals were classified according to predominant 
Aβ pattern while blind to the experimental variables (e.g. age, sex, pharmacological 
treatment or breed). 
3.1. Type I 
Aβ deposition was light in density, small in size (less than 180 
μm in diameter), and round in shape. These deposits were primarily 
restricted to layers V and VI and had obscure boundaries. These Aβ-
positive plaques were usually isolated and few in number (Fig. 2, Fig. 
3). The Type I pattern also contained fine fiber-like Aβ deposits around 
neurons (see Fig. 4). 
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Fig. 4. A: photomicrograph (×100) showing fine fiber-like Aβ immunoreactivity found 
in Type I Aβ deposition in the deep layers (V, VI) of canine frontal cortex. B: 
photomicrograph (100×) of Aβ-immunopositive tortuous fiber-like structures within 
the diffuse Aß-immunoreactive zone of Type II Aβ deposition in canine frontal cortex. 
These fibers were PHF-I negative. 
3.2. Type II 
Aβ deposition was diffuse, cloud-like, and located primarily 
within the deep layers of cortex (V and VI). These Aβ deposits typically 
had obscure boundaries and a conspicuous tendency to fuse together. 
The deposits usually extended horizontally for several millimeters, but 
sometimes they also extended superficially to layers IV and III, and 
occasionally even to layer II. Aβ-Immunopositive tortuous fiber-like 
structures were also observed within the diffuse Aβ-immunoreactive 
zone, especially in the deeper layers (see Figs. 3 and 4). 
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3.3. Type III 
Aβ deposition consisted of dense, round Aβ-positive plaques 
similar in morphological appearance to human senile plaques. They 
were usually less than 120 μm in diameter, but some exceeded 200 
μm. This type of Aβ deposit displayed fairly distinct superficial 
boundaries within layers I through III. Type III deposition was also 
accompanied by a deeper cloud-like diffuse Aβ deposit comparable to 
that seen in Type II Aβ deposition (see Fig. 2, Fig. 3). 
3.4. Type IV 
Aβ deposition consisted of dense, round Aβ positive plaques 
throughout all layers of frontal cortex, rather than being restricted to 
layers I-III as in Type III. Type IV deposition, which was more rare 
than Type III, also lacked the diffuse Aβ `cloud' in the deep cortical 
layers seen in Type III (see Fig. 2, Fig. 3). 
While blinded to the experimental conditions, the predominant 
type of Aβ deposition present was classified for each animal. We then 
compared the distribution of Aβ subtypes between the Old group, 
which was composed of 10- to 15-year old canines (n=22), and the 
Very Old group, which was composed of canines older than 15 years 
(n=19). 
Nearly 10% of the animals in the Old group displayed no Aβ-
immunoreactivity, with Aβ Types I and II most commonly found in this 
group. Indeed, these three Aβ patterns (negative, I and II) 
characterized 73% of the canines between the ages of 10 and 15 years 
(see Table 2). Conversely, all of the Very Old canines exhibited some 
Aβ deposition. Types II, III and IV characterized 89.5% of the Very 
Old group. Graphical representation revealed that there is a shift in the 
deposition pattern to the right with advancing age, such that Types I 
and II in the 10–15-year-old dogs give way to Types III and IV in the 
dogs older than 15 years (see Fig. 5). Comparison of the Old and Very 
Old groups by Mann–Whitney U analysis demonstrated a statistically 
significant difference between the deposition patterns (U=134.5, 
z=−2.04, P<0.05). There were no significant effects of tissue source, 
sex, breed, or monoamine oxidase inhibitor treatment on Aβ type. To 
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validate these results, Aβ type and age were submitted to simple and 
multiple regression models. Age was a significant predictor of Aβ 
deposition type (r=0.43, P=0.005), while breed, sex, and monoamine 
oxidase inhibitor treatment were not significant predictors. 
Table 2. Proportion of canine cases by age group exhibiting each of the 
patterns of Aβ deposition 
Dog age group No Aβ Type I Type II Type III Type IV 
10–15 years (22) 9.1% (2) 22.7% (5) 40.9% (9) 22.7% (5) 4.6% (1) 
>15 years (19) 0.0% (0) 10.5% (2) 36.8% (7) 36.8% (7) 15.9% (3) 
Raw numbers of cases are in parentheses. 
 
Fig. 5. Histogram depicting the change in proportion of Aβ deposition type between 
canines in the Old group (10–15 years) and the Very Old group (>15 years). There 
was a clear shift to the right, toward Types III and IV, in the Very Old group. 
If, as suggested by our observations, deeper layer plaques are 
deposited before more superficial layers, then a marker of amyloid 
`age' should be more prevalent in the deeper layers. β-Amyloid 
contains several aspartate residues that, over time, will isomerize to 
isoaspartate and could be detected with an antibody specific to β-
amyloid containing isoaspartate.28 Accordingly, an antibody was raised 
to β-amyloid where an isoaspartate was substituted for aspartate at 
position 7. The affinity purified antibody was found to be specific (see 
Section 2) and was used to determine if the presence of isoAsp7 β-
amyloid was preferentially distributed to specific layers. Only a 
proportion of plaques labeled with β-amyloid are also labeled with 
isoAsp7. In Type III and IV patterns of β-amyloid deposition, deep 
layer plaques, but few superficial layer plaques were positive for 
isoAsp7 (Fig. 6). This, along with the data on age-related changes, 
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supports the hypothesis that there is a sequence of plaque deposition 
in the canine frontal cortex which can be visualized as distinct patterns 
or `Types'. 
 
Fig. 6. Representative photomicrographs showing that deeper layer diffuse plaques 
containing Aβ typical of Type III (A) and Type IV (B) also contain isoAsp7 β-amyloid (C 
and D). 
The staining for PHF-1 was completely negative for cell bodies 
and fibers of neurons on the stained sections. SMI-311 was positive 
primarily in cell bodies of neurons but did not delineate Aβ-
immunopositive fibers. 
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4. Discussion 
We immunohistochemically examined frontal cortex tissue from 
41 canines who were 10 or more years of age to characterize Aβ 
deposits and the differences in their distribution with age. We 
identified four distinct patterns of Aβ deposition: rare, punctate 
deposits in the deep layers; large, deep, cloud-like deposits; and 
dense, round plaques traversing all cortical layers. There was a clear 
change in the pattern of Aβ deposition with advancing age, which did 
not appear to relate to the source, sex, or pharmacological history of 
the animals. Aβ deposition within the Old animals (10–15 years old) 
consisted predominantly of small deposits within the deep cortical 
layers and diffuse cloud-like deposits, also predominantly restricted to 
deeper layers (i.e. Types I and II). Within this group, negative 
staining, Type I, and Type II patterns accounted for 73% of the cases, 
with Type II being the most prominent pattern (41%). In contrast, the 
Very Old group (>15 years old) exhibited Type III and IV patterns 
much more frequently. In fact, Types II, III and IV made up 90% of 
Aβ deposition in the Very Old cases, with Type III occurring as 
frequently as Type II (37% each). 
Thus, with increasing age, there appeared to be a shift towards 
larger, denser Aβ deposits in the form of senile plaques, as well as 
greater deposition of Aβ in the superficial layers. Based on these 
observations, we hypothesize that the earliest deposition of Aβ occurs 
within the deep layers of frontal cortex (layers V and VI) in the canine. 
Over time, diffuse cloud-like extensions of Aβ also form in the deepest 
layers of cortex. Later, denser plaque-like deposits of Aβ form in the 
more superficial layers of cortex (i.e. II and III), and these deposits 
grow in size. The presence of deep layer diffuse plaques positive for 
isomerized aspartic acid residues also supports a progression 
hypothesis. Importantly, the median life expectancy of the canine 
population examined is just under 14 years (see Fig. 1) and yet Aβ 
deposition was commonly observed much earlier. Therefore, it appears 
that Aβ deposition begins in late middle age, rather than in the latest 
stages of life. 
We also observed fiber-like Aβ immunostaining within the deep 
cortical layers. We have previously described these fibers6 as 
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neurofilament-positive and Aβ-positive fibers; they are similar in 
morphological appearance to neuropil threads, which are nearly always 
observed in the AD brain.4 Braak et al. have indicated that neuropil 
threads may densely fill a layer without the presence of NFTs (e.g. 
layer V of striate cortex). Since these neuropil threads are important 
components of AD-related pathology, efforts to elucidate the 
conditions responsible for their development and pattern of distribution 
are valuable.4 In the canine brain, however, NFT changes have not 
been observed.6 Similarly, we did not detect PHF-1 or SMI-311 
immunoreactivity associated with Aβ-positive fibers in the present 
study. We suspect that the canine brain exhibits very early 
phosphorylation changes in nerve fibers, which cannot be detected 
with the antibodies that show tau pathology in AD brain. Alternatively, 
age-associated nerve fiber degeneration in the canine brain may be 
caused by a mechanism other than hyperphosphorylation of tau. For 
example, Migheli et al. argue that ubiquitin-positive fibers are present 
within the aged canine brain.21 
While it is clear that extensive Aβ deposition commonly occurs 
in the aged canine, the source of the Aβ found within the neuropil 
remains unknown. In a number of model systems, it has been 
confirmed that Aβ is secreted by neurons.1,5 Indeed, we often observe 
Aβ-filled neurons in the canine brain.6,8 In addition, Aβ is detectable in 
human cerebrospinal fluid.12,29,32,33 Therefore, there is likely to be an 
evacuation mechanism for Aβ from the parenchyma to the ventricular 
system. Furthermore, it has been reported that APP is produced in the 
cell body of neurons and is carried by anterograde fast axonal flow to 
nerve endings and, at sites of amyloid deposition, is aberrantly 
processed into Aβ.19 This raises the possibility that either 
overproduction of APP and Aβ, abnormal axonal flow, or abnormal 
clearance of Aβ are the cause of Aβ deposition in the aged brain. It is 
also possible that more than one of these factors contributes to the 
problem. 
Our observations of fiber-like Aβ staining within deep layers of 
frontal cortex and the diffuse deposits surrounding them in the 
neuropil (Fig. 4) are consistent with the suggestion that Aβ deposition 
is initiated at the nerve terminal.23 These Aβ-immunopositive fibers 
may therefore be an expression of early Aβ deposition originating in 
corticocortical projections16 from layers II and III to deeper layers. 
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Later in time, Aβ deposits may form around the cell bodies of these 
projecting neurons. Indeed, we observed that the dense round-shaped 
Aβ deposits in the Type III pattern were localized around the neurons 
in layers II and III. These results have important implications for the 
relationship between Aβ and nerve fiber degeneration in the aged 
canine. For example, it has been reported that axonal degeneration 
promotes abnormal accumulation of Aβ in the ascending gracile tract 
of the gracile axonal dystrophy mouse.17 
There were remarkable similarities between the late-stage Aβ 
deposition patterns of aged canines and that in AD brain. First, Type 
III and IV canine plaques resembled the human senile plaques 
observed in AD brain, although other studies have shown that canine 
plaques did not exhibit β-pleated structure and they were larger than 
typical AD plaques.8 Second, Type III Aβ deposition demonstrated a 
laminar distribution, primarily in layers II and III. On the other hand, 
Type IV Aβ deposition, where canine plaques appeared even more 
similar in shape to human senile plaques, was scattered across all 
layers with no laminar specificity. This pattern was comparable to the 
irregular laminar distribution of plaques in AD brain.4 
Our observations in the canine brain suggest that the process of 
Aβ deposition is multiphasic, exhibiting different morphological and 
laminar characteristics over time. Thus, the laminar distribution of 
senile plaques may become obscured in human brain as AD reaches 
advanced stages. Moreover, it has been reported that as the severity 
of dementia increases, the density of mature plaques generally 
increases, but that of primitive plaques decreases, such that there 
tends to be an overall decrease in total plaque density.25 This makes 
analysis of the distribution of Aβ deposition in AD brain complex, 
especially using general histological staining methods. Therefore, the 
interpretation of results from previous reports of Aβ distribution in AD 
brain may have been obscured by the inclusion of observations from 
patients at several different stages of AD pathology. 
In this study, we found diffuse Aβ deposits in the deep layers of 
frontal cortex. This morphology has not been reported in aged human 
or AD brain. This phenomenon may be a very early event in the 
deposition of Aβ in frontal cortex, making it difficult to observe in 
human brain. Alternatively, it may be a pattern specific to the aged 
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canine. This issue remains to be clarified. As the aged canine model of 
Aβ deposition is further characterized and refined, it will certainly be 
important for testing hypotheses about Aβ deposition and plaque 
formation in human aging and AD. 
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